Navigation Links
CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Date:7/10/2008

PALO ALTO, Calif., July 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has received marketing authorization from the European Medicines Agency (EMEA) for ranolazine for the treatment of patients with chronic angina in all 27 European Union (EU) member states. This approval follows a positive opinion from the EMEA Committee for Medicinal Products for Human Use (CHMP) on April 24, 2008.

Ranolazine is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. Ranolazine is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily.

The approved European labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce cellular calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness.

"We expect ranolazine could be available to patients and physicians across Europe beginning in the first part of 2009, as we continue to see very strong interest from potential commercial partners," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "Revenues from European sales of ranolazine would represent a fourth product-related revenue stream for CV Therapeutics."

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy).

"Considering the well-established ne
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. Nabriva Therapeutics Announces Appointment of New CEO
4. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
7. Tobira Therapeutics Inc. Announces Senior Management Team
8. Duska Therapeutics Obtains Standard & Poors Listing
9. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
10. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
11. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. (OTCQB: ... 400 million people worldwide are living with diabetes, with  ... by 2030.  The global market for diabetes treatments is ... 330,000 people worldwide died from pancreatic cancer.  Pancreatic cancer ... to cancer in the United States ...
(Date:10/20/2014)... Convey Computer , the leader ... Iowa State University won first place in the ... HC-2ex, the team’s solution achieved the highest overall performance ... second place finisher. , Experts from all segments of ... long challenge, using a variety of design tools, hardware ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Capabilities ... & Team, CANTON, Mass. and BATON ROUGE, ... successful regenerative medicine,company, announced today the strategic acquisition ... develops "designer scaffolds" for the,purposes of regenerative medicine, ...
... RESEARCH TRIANGLE PARK, N.C., Feb. 25 ... tools for signal,transduction analysis, announced today that ... flagmanship technology, the FACTORIAL(TM). In,advance online publication ... colleagues describes a novel and remarkably consistent ...
... Feb. 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... initiated,its first Phase 3 clinical trial with ... candidate being developed for the treatment of,acute ... disorder. Alexza,believes the novel, non-invasive nature and ...
Cached Biology Technology:Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 2Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 3Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... fly genome for the first time, revealing robust immune ... thrives in pathogen-rich dung piles and garbage heaps. , ... Genome Biology , will increase understanding of house fly ... to resist insecticides, which could lead to novel control ... transmit more than 100 human and animal diseases, including ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... awarded two Clemson chemistry faculty nearly $1 million to ... McNeill and Ken Christensen will receive the $960,000 grant ... in live cells. The development of techniques for ... could use this technology to determine the bodys defenses ...
... Mo. Heart disease is the leading cause of ... quality and length of life for individuals with specific ... gene and/or stem cell therapy could help a variety ... have been unsure whether the heart could benefit from ...
... the superhero cure for viral infections, may be ... infections in immunocompromised patients, according to an article ... Fungal infections (mycoses) were once seen as exotic ... life-threatening in healthy patients, fungal infections are a ...
Cached Biology News:NIH recognizes Clemson nanotechnology for molecule tracking 2Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart 2Gamma interferon could aid fight against fungal infections 2
... Ease of Use : GeneTraffic ... software tool for biological research. GeneTraffic provides ... to validate your data prior to analysis. ... Quickly define your projects using the MIAME ...
... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: